patents.google.com

SG11201408095XA - Fibroblast growth factor 21 proteins - Google Patents

️Thu Jan 29 2015

SG11201408095XA - Fibroblast growth factor 21 proteins - Google Patents

Fibroblast growth factor 21 proteins

Info

Publication number

SG11201408095XA

SG11201408095XA SG11201408095XA SG11201408095XA SG11201408095XA SG 11201408095X A SG11201408095X A SG 11201408095XA SG 11201408095X A SG11201408095X A SG 11201408095XA SG 11201408095X A SG11201408095X A SG 11201408095XA SG 11201408095X A SG11201408095X A SG 11201408095XA Authority

Singapore

Prior art keywords

indiana

indianapolis

company

international

eli lilly

Prior art date

2012-06-11

Application number

SG11201408095XA

Inventor

Ryan James Darling

Craig Duane Dickinson

David Albert Driver

Malgorzata Donata Gonciarz

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-06-11

Filing date

2013-06-05

Publication date

2015-01-29

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48670814&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201408095X(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2013-06-05 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

2015-01-29 Publication of SG11201408095XA publication Critical patent/SG11201408095XA/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
- Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
- Y10S530/813—Carrier is a saccharide
- Y10S530/814—Cellulose or derivatives thereof

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Toxicology (AREA)
Immunology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Obesity (AREA)
Hematology (AREA)
Epidemiology (AREA)
Emergency Medicine (AREA)
Child & Adolescent Psychology (AREA)
Endocrinology (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 19 December 2013 (19.12.2013) WIPOIPCT (10) International Publication Number WO 2013/188181 A1 (51) International Patent Classification: A61K38/18 (2006.01) C07K14/50 (2006.01) (21) International Application Number: (22) International Filing Date: (25) Filing Language: (26) Publication Language: PCT/US2013/044190 5 June 2013 (05.06.2013) English English (30) Priority Data: 61/658,104 61/777,386 11 June 2012 (11.06.2012) US 12 March 2013 (12.03.2013) US (71) Applicant: ELI LILLY AND COMPANY [US/US]; Lilly Corporate Center, Indianapolis, Indiana 46285 (US). (72) Inventors: DARLING, Ryan James; c/o Eli Lilly and Company, P.O. Box 6288, Indianapolis, Indiana 46206- 6288 (US). DICKINSON, Craig Duane; c/o Eli Lilly and Company, P.O. Box 6288, Indianapolis, Indiana 46206- 6288 (US). DRIVER, David Albert; c/o Eli Lilly and Company, P. O. Box 6288, Indianapolis, Indiana 46206- 6288 (US). GONCIARZ, Malgorzata Donata; c/o Eli Lilly and Company, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US). (74) Agents: CASTETTER, Andrea M. et al.; Eli Lilly and Company, P. O. Box 6288, Indianapolis, Indiana 46206- 6288 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available)'. AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available)'. ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17 : — as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(H)) — as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: — with international search report (Art. 21(3)) — with sequence listing part of description (Rule 5.2(a)) 00 i-H 00 00 i-H o CJ (54) Title: FIBROBLAST GROWTH FACTOR 21 PROTEINS (57) Abstract: This present invention relates to pharmacologically potent and stable human fibroblast growth factor 21 (FGF21) proteins, pharmaceutical compositions comprising FGF21 proteins, and methods for treating type 2 diabetes, obesity, dyslipidemia, and/or metabolic syndrome using such proteins.

SG11201408095XA 2012-06-11 2013-06-05 Fibroblast growth factor 21 proteins SG11201408095XA (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201261658104P	2012-06-11	2012-06-11
US201361777386P	2013-03-12	2013-03-12
PCT/US2013/044190 WO2013188181A1 (en)	2012-06-11	2013-06-05	Fibroblast growth factor 21 proteins

Publications (1)

Publication Number	Publication Date
SG11201408095XA true SG11201408095XA (en)	2015-01-29

Family

ID=48670814

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG11201408095XA SG11201408095XA (en)	2012-06-11	2013-06-05	Fibroblast growth factor 21 proteins

Country Status (24)

Country	Link
US (2)	US8741841B2 (en)
EP (1)	EP2858662B1 (en)
JP (1)	JP6182600B2 (en)
KR (1)	KR20150006060A (en)
CN (1)	CN104394882B (en)
AR (1)	AR091216A1 (en)
AU (1)	AU2013274638A1 (en)
BR (1)	BR112014029966A2 (en)
CA (1)	CA2871145A1 (en)
CL (1)	CL2014003078A1 (en)
CO (1)	CO7151525A2 (en)
EA (1)	EA201492053A1 (en)
EC (1)	ECSP14030742A (en)
ES (1)	ES2644787T3 (en)
HK (1)	HK1203357A1 (en)
IL (1)	IL235832A0 (en)
IN (1)	IN2014MN02132A (en)
MX (1)	MX2014015257A (en)
PE (1)	PE20150201A1 (en)
PH (1)	PH12014502766A1 (en)
SG (1)	SG11201408095XA (en)
TN (1)	TN2014000439A1 (en)
TW (1)	TWI513705B (en)
WO (1)	WO2013188181A1 (en)

Families Citing this family (46)

* Cited by examiner, † Cited by third party

Publication number	Priority date	Publication date	Assignee	Title
KR20160121601A (en)	2007-03-30	2016-10-19	암브룩스, 인코포레이티드	Modified fgf-21 polypeptides and their uses
PT2726511T (en)	2011-07-01	2019-10-14	Ngm Biopharmaceuticals Inc	Compositions, uses and methods for treatment of metabolic disorders and diseases
TWI513705B (en)	2012-06-11	2015-12-21	Lilly Co Eli	Fibroblast growth factor 21 proteins
KR20150006059A (en) *	2012-06-11	2015-01-15	일라이 릴리 앤드 캄파니	Fibroblast growth factor 21 variants
US9290557B2 (en)	2012-11-28	2016-03-22	Ngm Biopharmaceuticals, Inc.	Compositions comprising variants and fusions of FGF19 polypeptides
EP3798228A1 (en)	2012-11-28	2021-03-31	NGM Biopharmaceuticals, Inc.	Compositions and methods for treatment of metabolic disorders and diseases
US9273107B2 (en)	2012-12-27	2016-03-01	Ngm Biopharmaceuticals, Inc.	Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
EP4083221A1 (en)	2012-12-27	2022-11-02	NGM Biopharmaceuticals, Inc.	Chimeric fgf19 peptides for use in treating bile acid disorders
SG11201602870YA (en)	2013-10-28	2016-05-30	Ngm Biopharmaceuticals Inc	Cancer models and associated methods
PT3097122T (en)	2014-01-24	2020-07-21	Ngm Biopharmaceuticals Inc	Binding proteins and methods of use thereof
MX2016009858A (en) *	2014-02-21	2017-01-26	Medimmune Llc	Anti-pcsk9~glp-1 fusions and methods for use.
EP3125921B1 (en)	2014-03-11	2020-07-08	Novartis AG	Fgf21 variants for use in treating hiv-haart induced partial lipodystrophy
AU2015236073B2 (en)	2014-03-25	2020-04-30	Regeneron Pharmaceuticals, Inc.	FGF21 receptor agonists and uses thereof
US10398758B2 (en)	2014-05-28	2019-09-03	Ngm Biopharmaceuticals, Inc.	Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions
EP3155005A4 (en)	2014-06-16	2018-07-11	NGM Biopharmaceuticals, Inc.	Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
JP6308699B2 (en) *	2014-09-08	2018-04-11	国立大学法人大阪大学	Preventive or therapeutic agent for demyelinating disease
UA123763C2 (en)	2014-10-23	2021-06-02	Енджіем Байофармасьютикалз, Інк.	PHARMACEUTICAL COMPOSITION FOR CONTROL OR TREATMENT OF FGF19 DISEASE OR DISORDER
SMT202100388T1 (en)	2014-10-24	2021-09-14	Bristol Myers Squibb Co	Modified fgf-21 polypeptides and uses thereof
WO2016073855A1 (en)	2014-11-07	2016-05-12	Ngm Biopharmaceuticals, Inc.	Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
KR20160088656A (en)	2015-01-16	2016-07-26	주식회사유한양행	Long-acting fgf21 fusion proteins and pharmaceutical composition comprising the same
US11638745B2 (en)	2015-05-20	2023-05-02	University of Pittsburgh—Of the Commonwealth Cvctom of Hierher Education	Method to improve neurologic outcomes in temperature managed patients
US10800843B2 (en)	2015-07-29	2020-10-13	Ngm Biopharmaceuticals, Inc.	Beta klotho-binding proteins
KR102670157B1 (en)	2015-10-28	2024-05-29	주식회사유한양행	Dual function proteins and pharmaceutical composition comprising the same
KR102668200B1 (en) *	2015-10-28	2024-05-23	주식회사유한양행	Long-acting fgf21 fusion proteins and pharmaceutical composition comprising the same
US10744185B2 (en)	2015-11-09	2020-08-18	Ngm Biopharmaceuticals, Inc.	Methods of using variants of FGF19 polypeptides for the treatment of pruritus
CN105348380B (en) *	2015-12-28	2019-03-01	江苏康缘瑞翱生物医药科技有限公司	Dog fibroblast growth factor 21 and its purposes in treatment dog endocrine system disease
CN106317226B (en)	2016-08-19	2017-09-05	安源医药科技（上海）有限公司	Linker peptide for construction of fusion proteins
CN106279437B (en)	2016-08-19	2017-10-31	安源医药科技（上海）有限公司	Hyperglycosylated human coagulation factor VIII fusion proteins and preparation method thereof and purposes
WO2018032638A1 (en)	2016-08-19	2018-02-22	安源医药科技（上海）有限公司	Linker peptide for constructing fusion protein
EP3503882A4 (en)	2016-08-26	2020-07-29	NGM Biopharmaceuticals, Inc.	Methods of treating fibroblast growth factor 19-mediated cancers and tumors
BR112019009581A2 (en) *	2016-11-10	2019-10-08	Yuhan Corp	pharmaceutical composition for preventing or treating hepatitis, liver fibrosis, and liver cirrhosis comprising fusion proteins
CN108570109B (en)	2017-03-14	2022-04-26	广东东阳光药业有限公司	Dual target fusion proteins comprising an immunoglobulin Fc portion
US11560416B2 (en)	2017-04-21	2023-01-24	Yuhan Corporation	Method for producing dual function proteins and its derivatives
CN107385020A (en) *	2017-06-23	2017-11-24	西安医学院	Application of the leptin in people recombinates the detection of FGF21 protein actives
EP3678686A1 (en)	2017-09-08	2020-07-15	Bristol-Myers Squibb Company	Modified fibroblast growth factor 21 (fgf-21) for use in methods for treating nonalcoholic steatohepatitis (nash)
WO2019154189A1 (en)	2018-02-08	2019-08-15	Sunshine Lake Pharma Co., Ltd.	Fgf21 variant, fusion protein and application thereof
BR112020026512A2 (en)	2018-07-03	2021-04-06	Bristol-Myers Squibb Company	FGF-21 FORMULATIONS
CN111195234B (en) *	2018-11-16	2022-08-26	鲁南制药集团股份有限公司	Recombinant FGF21-Fc fusion protein freeze-dried powder preparation
CN111662373B (en) *	2019-03-05	2024-05-14	广东东阳光药业股份有限公司	Polypeptide molecule and application thereof
AR122359A1 (en)	2020-01-08	2022-09-07	Bristol Myers Squibb Co	FGF-21 CONJUGATE FORMULATIONS
US11981718B2 (en)	2020-05-27	2024-05-14	Ampsource Biopharma Shanghai Inc.	Dual-function protein for lipid and blood glucose regulation
JP2023538533A (en)	2020-08-07	2023-09-08	ブリストル－マイヤーズスクイブカンパニー	FGF21 in combination with CCR2/5 antagonists for the treatment of fibrosis
KR20220021207A (en)	2020-08-13	2022-02-22	주식회사 나이벡	BMP-9 or BMP-10 variants with improved therapeutic effect by reducing the side effects of ossicle formation and a pharmaceutical composition using the same
KR102495299B1 (en) *	2020-11-03	2023-02-06	토드제약 주식회사	Methods for producing fgf21 using heat-elasticity of fgf21
US20240123031A1 (en)	2020-11-25	2024-04-18	Bristol-Myers Squibb Company	Methods of treating liver diseases
KR102631925B1 (en) *	2021-06-10	2024-02-01	토드제약 주식회사	Development of novel fgf21 variants, production techniques and uses thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party

Publication number	Priority date	Publication date	Assignee	Title
GB8601597D0 (en)	1986-01-23	1986-02-26	Wilson R H	Nucleotide sequences
US7459540B1 (en)	1999-09-07	2008-12-02	Amgen Inc.	Fibroblast growth factor-like polypeptides
WO2003011213A2 (en)	2001-07-30	2003-02-13	Eli Lilly And Company	Method for treating diabetes and obesity
KR20060135648A (en)	2003-12-10	2006-12-29	일라이 릴리 앤드 캄파니	Muteins of Fibroblast Growth Factor 21
JP2008506635A (en)	2004-05-13	2008-03-06	イーライリリーアンドカンパニー	FGF-21 fusion protein
KR20160121601A (en) *	2007-03-30	2016-10-19	암브룩스, 인코포레이티드	Modified fgf-21 polypeptides and their uses
JOP20190083A1 (en) *	2008-06-04	2017-06-16	Amgen Inc	Fgf21 mutant fusion polypeptides and uses thereof
CH699521A2 (en)	2008-09-09	2010-03-15	Rotorcraft Ag	Drafting arrangement for a knitting machine.
EP2358749B1 (en)	2008-10-10	2018-07-18	Amgen, Inc	Fgf21 mutants and uses thereof
WO2010065439A1 (en) *	2008-12-05	2010-06-10	Eli Lilly And Company	Variants of fibroblast growth factor 21
MX2011007544A (en)	2009-01-23	2011-08-12	Novo Nordisk As	Fgf21 derivatives with albumin binder a-b-c-d-e- and their use.
AU2010246038A1 (en) *	2009-05-05	2011-12-01	Amgen Inc.	FGF21 mutants and uses thereof
JO3469B1 (en)	2009-05-05	2020-07-05	Amgen Inc	FGF21 mutants and their uses
JP2013533227A (en) *	2010-06-08	2013-08-22	ノヴォノルディスクアー／エス	FGF21 analogs and derivatives
AR087973A1 (en) *	2011-10-04	2014-04-30	Lilly Co Eli	VARIATIONS OF FACTOR 21 GROWTH OF FIBROBLASTS
TWI513705B (en)	2012-06-11	2015-12-21	Lilly Co Eli	Fibroblast growth factor 21 proteins

2013
- 2013-05-27 TW TW102118698A patent/TWI513705B/en not_active IP Right Cessation
- 2013-05-30 AR ARP130101904 patent/AR091216A1/en unknown
- 2013-06-05 WO PCT/US2013/044190 patent/WO2013188181A1/en active Application Filing
- 2013-06-05 ES ES13730733.6T patent/ES2644787T3/en active Active
- 2013-06-05 EA EA201492053A patent/EA201492053A1/en unknown
- 2013-06-05 BR BR112014029966A patent/BR112014029966A2/en not_active IP Right Cessation
- 2013-06-05 SG SG11201408095XA patent/SG11201408095XA/en unknown
- 2013-06-05 CN CN201380030788.4A patent/CN104394882B/en not_active Expired - Fee Related
- 2013-06-05 MX MX2014015257A patent/MX2014015257A/en unknown
- 2013-06-05 AU AU2013274638A patent/AU2013274638A1/en not_active Abandoned
- 2013-06-05 EP EP13730733.6A patent/EP2858662B1/en active Active
- 2013-06-05 US US13/910,149 patent/US8741841B2/en active Active
- 2013-06-05 IN IN2132MUN2014 patent/IN2014MN02132A/en unknown
- 2013-06-05 KR KR20147034366A patent/KR20150006060A/en not_active Abandoned
- 2013-06-05 CA CA2871145A patent/CA2871145A1/en not_active Abandoned
- 2013-06-05 PE PE2014002236A patent/PE20150201A1/en not_active Application Discontinuation
- 2013-06-05 JP JP2015517297A patent/JP6182600B2/en active Active
2014
- 2014-04-23 US US14/259,210 patent/US8927492B2/en active Active
- 2014-10-20 TN TN2014000439A patent/TN2014000439A1/en unknown
- 2014-11-13 CL CL2014003078A patent/CL2014003078A1/en unknown
- 2014-11-20 IL IL235832A patent/IL235832A0/en unknown
- 2014-11-27 CO CO14261559A patent/CO7151525A2/en unknown
- 2014-12-10 PH PH12014502766A patent/PH12014502766A1/en unknown
- 2014-12-11 EC ECIEPI201430742A patent/ECSP14030742A/en unknown
2015
- 2015-04-20 HK HK15103818.7A patent/HK1203357A1/en unknown

Also Published As

Publication number	Publication date
JP6182600B2 (en)	2017-08-16
TW201408693A (en)	2014-03-01
PH12014502766A1 (en)	2015-02-09
EA201492053A1 (en)	2015-02-27
US8927492B2 (en)	2015-01-06
US8741841B2 (en)	2014-06-03
ES2644787T3 (en)	2017-11-30
TN2014000439A1 (en)	2016-03-30
KR20150006060A (en)	2015-01-15
PE20150201A1 (en)	2015-02-19
AU2013274638A1 (en)	2014-11-06
US20130330336A1 (en)	2013-12-12
CL2014003078A1 (en)	2015-02-27
EP2858662B1 (en)	2017-08-09
US20140228282A1 (en)	2014-08-14
AR091216A1 (en)	2015-01-21
IL235832A0 (en)	2015-01-29
TWI513705B (en)	2015-12-21
CO7151525A2 (en)	2014-12-29
WO2013188181A1 (en)	2013-12-19
CA2871145A1 (en)	2013-12-19
BR112014029966A2 (en)	2017-09-12
EP2858662A1 (en)	2015-04-15
CN104394882B (en)	2016-06-22
HK1203357A1 (en)	2015-10-30
MX2014015257A (en)	2015-03-05
ECSP14030742A (en)	2015-09-30
JP2015527974A (en)	2015-09-24
CN104394882A (en)	2015-03-04
IN2014MN02132A (en)	2015-09-11

Publication	Publication Date	Title
SG11201408095XA (en)	2015-01-29	Fibroblast growth factor 21 proteins
SG11201909022PA (en)	2019-11-28	ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
SG11201407655TA (en)	2014-12-30	Therapeutic uses of fibroblast growth factor 21 proteins
SG11201810628XA (en)	2018-12-28	Nasal pharmaceutical compositions with a porous excipient
SG11201908567UA (en)	2019-10-30	Modified cyclic dinucleotide compounds
SG11201407580YA (en)	2014-12-30	Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201805320XA (en)	2018-07-30	Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration
SG11201408261UA (en)	2015-01-29	Syringe
SG11201909680UA (en)	2019-11-28	Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
SG11201900844UA (en)	2019-02-27	Amino pyrimidine ssao inhibitors
SG11201408646VA (en)	2015-01-29	Dimeric protein with triple mutations
SG11201907604UA (en)	2019-09-27	Crystalline forms of the 4-pyrimidinesulfamide derivative aprocitentan
SG11201803920TA (en)	2018-06-28	Compounds and compositions useful for treating disorders related to ntrk
SG11201907804QA (en)	2019-09-27	Pharmaceutical composition comprising selexipag
SG11201408174UA (en)	2015-01-29	Antibody formulation
SG11201408318RA (en)	2015-01-29	Compositions and methods for transmucosal absorption
SG11201403106SA (en)	2014-12-30	Anti-phf-tau antibodies and their uses
SG11201907032RA (en)	2019-08-27	Amino pyrimidine compounds useful as ssao inhibitors
SG11201408037SA (en)	2015-01-29	Humanized anti-trka antibodies with amino acid substitutions
SG11201908512YA (en)	2019-10-30	Somatostatin modulators and uses thereof
SG11201810371XA (en)	2018-12-28	ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
SG11201408641UA (en)	2015-01-29	Phenoxyethyl piperidine compounds
SG11201906436VA (en)	2019-08-27	Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201404836QA (en)	2014-12-30	Long-acting coagulation factors and methods of producing same
SG11201407801VA (en)	2014-12-30	Methods for use of mixed multifunctional surfaces for reducing aggregate content in protein preparations

SG11201408095XA - Fibroblast growth factor 21 proteins - Google Patents